In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV1 reversibility.

ABSTRACT: Background:A post hoc analysis of two randomized, placebo-controlled, Phase 3 trials of intravenous reslizumab, an anti-interleukin-5 (IL-5) biologic for severe eosinophilic asthma. Methods:Relationships between baseline blood eosinophil levels (EOS), forced expiratory volume in 1 s (FEV1) reversibility to ?2-agonists and treatment outcomes were assessed. Results:Mean baseline FEV1 reversibility was numerically lower among patients with high (??400 cells/µL) versus low baseline EOS. Reslizumab produced clinically significant improvement in FEV1, exacerbation rates and patient-reported outcomes after 52 weeks, including in patients with high EOS and low FEV1 reversibility (??14%) to ?2-agonists at baseline. Conclusions:Clinical trial eligibility criteria stipulating minimum FEV1 reversibility to ?2-agonists of???12% might exclude patients who would benefit from treatment with anti-IL-5 biologics.

SUBMITTER: Virchow JC 

PROVIDER: S-EPMC7168990 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature